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Abstract 
Purpose: Acute kidney injury (AKI) frequently occurs after heart transplantation (HTx), but its relation to preoperative 
right heart hemodynamic (RHH) parameters remains unknown. Therefore, we aimed to determine their predictive 
properties for postoperative AKI severity within 30 days after HTx.
Methods: From 1984 to 2016, all consecutive HTx recipients (n = 595) in our tertiary referral center were included and 
analyzed for the occurrence of postoperative AKI staged by the kidney disease improving global outcome criteria. The 
effects of preoperative RHH parameters on postoperative AKI were calculated using logistic regression, and predictive 
accuracy was assessed using integrated discrimination improvement (IDI), net reclassification improvement (NRI), and 
area under the receiver operating characteristic curves (AUC).
Results: Postoperative AKI occurred in 430 (72%) patients including 278 (47%) stage 1, 66 (11%) stage 2, and 86 (14%) 
stage 3 cases. Renal replacement therapy (RRT) was administered in 41 (7%) patients. Patients with higher AKI stages 
had also higher baseline right atrial pressure (RAP; median 7, 7, 8, and in RRT 11 mmHg, p trend = 0.021), RAP-to-pulmo-
nary capillary wedge pressure ratio (median 0.37, 0.36, 0.40, 0.47, p trend = 0.009), and lower pulmonary artery pulsatil-
ity index (PAPi) values (median 2.83, 3.17, 2.54, 2.31, p trend = 0.012). Higher RAP and lower PAPi values independently 
predicted AKI severity [adjusted odds ratio (OR) per doubling of RAP 1.16 (1.02–1.32), p = 0.029; of PAPi 0.85 (0.75–0.96), 
p = 0.008]. Based on IDI, NRI, and delta AUC, inclusion of these parameters improved the models’ predictive accuracy.
Conclusions: Preoperative PAPi and RAP strongly predict the development of AKI early after HTx and can be used as 
early AKI predictors.
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Introduction
Heart transplantation (HTx) remains the gold stand-
ard therapy for patients with end-stage heart failure 
(HF), improving both their survival and quality of life 
[1]. Recent advances in immunosuppressive therapy 
and treatment protocols have significantly improved 
the long-term outcome in HTx recipients despite the 
propensity for accepting older donors [2]. However, the 
short-term outcome during the early postoperative phase 
has remained complex, affecting both morbidity and 
mortality [2, 3].
Acute kidney injury (AKI) occurs frequently after HTx, 
ranging from 22 to 76% and carries unfavorable progno-
sis [4–7]. In addition to anesthesia- and surgery-related 
factors that can precipitate AKI, postoperatively used 
nephrotoxic drugs (e.g., CNI) and hemodynamic instabil-
ity may also lead to AKI [4].
It is known that preexisting pulmonary hyperten-
sion increases right ventricular afterload that can lead 
to right ventricular failure (RVF) [8]. Importantly, RVF 
can critically diminish renal function by increasing renal 
venous pressure, causing congestive AKI [9, 10]. Conse-
quently, the right heart hemodynamic (RHH) parameters 
have been routinely assessed in all HTx candidates [11]. 
However, it is unclear how these RHH parameters relate 
to RVF and, more importantly, to AKI early after HTx. 
Finally, the question remains whether and to what extent 
is the relationship between preoperative RHH param-
eters and the occurrence of postoperative AKI explained 
by the occurrence of RVF along that pathway.
Recently, new composite hemodynamic parameters 
such as the pulmonary artery pulsatility index (PAPi), 
the right atrial pressure-to-pulmonary capillary wedge 
pressure ratio (RAP-to-PCWP), and diastolic pulmonary 
gradient (DPG) are considered to be predictors of RVF 
[12–15]. However, their relationships with postoperative 
AKI early after HTx remain unknown.
The aim of this study was to determine the predictive 
properties of routine and novel RHH parameters meas-
ured at the time of transplantation listing in relation to 
AKI early after HTx. Preliminary results have been previ-
ously reported [16].
Methods
Study population
Data of all consecutive HTx in the Erasmus Medi-
cal Center, Rotterdam, have been collected prospec-
tively since the first transplantation in June 1984 [2, 4]. 
We included all adult (≥ 18  years) patients transplanted 
between 1984 and December 2016. Patients were 
excluded if age < 18 years at the time of transplantation, 
were on renal replacement therapy (RRT) before trans-
plantation, died within 48  h, or were re-transplanted 
within 7  days after transplantation (Fig.  1). No patients 
underwent simultaneous heart/kidney transplantation. 
Patient data were obtained from the hospital database, 
electronic records, and by chart review.
Immunosuppressive protocol
From 1984 to 1999, immunosuppressive therapy con-
sisted of calcineurin inhibitor (CNI) cyclosporine A and 
tacrolimus thereafter. In patients who did not receive 
induction therapy, CNI was initiated peri-operatively 
or immediately after HTx. Induction therapy was used 
to delay the starting of CNI, especially in patients with 
already impaired kidneys and/or postoperative hemo-
dynamic instability, to postpone CNI nephrotoxicity [4]. 
Induction therapy consisted of anti-CD3 (1987–1994), 
anti-IL-2 (1987–1994), horse polyclonal anti-thymocyte 
globulin (1987–2008), and rabbit anti-thymocyte globu-
lin (2008 and thereafter).
Preoperative right heart catheterization parameters
All HTx candidates underwent right heart catheterization 
during the screening for transplantation listing. If a patient’s 
clinical status deteriorated with suspicion of pulmonary 
hypertension while on the waiting list, an additional cath-
eterization was performed where the most recent data prior 
to HTx were used for our analysis. Procedural data were 
extracted from the catheterization reports and included the 
following parameters: RAP, PCWP, pulmonary artery (PA) 
systolic, diastolic, and mean pressures, systemic arterial sys-
tolic, diastolic, and mean pressures, cardiac output, pulmo-
nary vascular resistance, systemic vascular resistance, PAPi, 
transpulmonary gradient (TPG), and DPG (Fig. 2) [13, 15].
Fig. 1 Flowchart of study population according to postoperative AKI 
severity. AKI acute kidney injury, RRT renal replacement therapy
Take-home message 
Novel composite right heart hemodynamic parameter pulmonary 
artery pulsatility index (PAPi), may outperform currently assessed 
parameters like transpulmonary gradient, diastolic pulmonary gradi-
ent and pulmonary vascular resistance. PAPi and right atrial pressure 
can be used as predictors for early AKI in patients undergoing heart 
transplantation, and early prediction of AKI could be used to timely 
treat high-risk patients.
Renal function assessment
Serum creatinine was measured as part of routine clini-
cal care at baseline, daily from postoperative day 0 until 
day 7, and at 1, 3, 6, 9, and 12  months. Baseline creati-
nine was defined as the most recent outpatient value up 
to 6  months before transplantation. If unavailable, cre-
atinine values at hospital admission were accepted as the 
baseline. Estimated glomerular filtration rate (eGFR) was 
assessed by the CKD-EPI equation [17], and categoriza-
tion was performed by National Kidney Foundation-Kid-
ney Disease Outcome Quality Initiative clinical practice 
guidelines [18].
Follow‑up and study endpoints
The primary endpoint was AKI severity as defined by kid-
ney disease improving global outcome (KDIGO) criteria 
during the first month after HTx. AKI stage 1 was defined 
as serum creatinine increased by ≥ 0.3 mg/dl (≥ 26.5 µmol/l) 
within 48  h or by 1.5–1.9 times baseline; AKI stage 2 as 
serum creatinine increased 2.0–2.9 times from baseline; 
and AKI stage 3 as serum creatinine increased 3.0 times 
from baseline or by ≥ 4.0 mg/dl (≥ 353.6 µmol/l) or starting 
RRT [19]. The time interval between HTx and the RRT was 
recorded within the first month. RRT requirement at 1 year 
was evaluated in all survivors.
The secondary endpoints were postoperative RVF and 
1-year survival. RVF was defined as need of postopera-
tive RVAD or as reported in the medical reports by the 
attending physicians. Post-discharge survival status was 
obtained from our hospital’s electronic patient file and 
was completed for all patients.
Statistical analysis
For reasons of uniformity, all continuous variables are 
presented as median (interquartile range, IQR) and cat-
egorical variables are presented as numbers and per-
centages. The distributions of continuous variables were 
tested for normality by the Kolmogorov–Smirnov test, 
and, if skewed, were  2log-transformed. For continuous 
variables, the linear trend across AKI stages was per-
formed by analysis of variance (ANOVA) or the Kruskal–
Wallis test, when appropriate; categorical variables were 
tested by the χ2 trend test.
Ordinal logistic regression analysis was performed to 
relate perioperative data to postoperative AKI severity 
(i.e., deterioration to any level of AKI). Covariates that 
were univariably associated with AKI severity (explora-
tory p < 0.10) were entered into a multivariable model, 
applying proportional odds ordinal regression with a full 
likelihood ratio method. All analyses were performed 
in the total cohort, and subsequently in the subgroup of 
patients with RAP ≥ 6 mmHg (previously determined as 
the cut-off for the opening of the collapsed vein) [20, 21]. 
A multiplicative interaction between dichotomized RAP 
and PAPi was also explored.
We assessed predictive accuracy for the most severe 
AKI (stage 3) before and after adding significant hemo-
dynamic parameters (p < 0.05) into the clinical model 
using the delta between the areas under the two receiver 
operating characteristic curves (AUC), integrated dis-
crimination improvement (IDI), and net reclassification 
improvement (NRI) [22, 23]. Clinical variables found 
to be univariably associated with AKI stage 3 (explora-
tory p < 0.10) were entered into a multivariable model 
using the stepwise backward likelihood ratio method. 
Only clinical predictors with p < 0.05 in the multivari-
able model were used to assess the models’ predictive 
accuracy.
Binary logistic regression analysis was applied to assess 
the association between RRT administration within 
30 days after HTx and chronic RRT dependency at 1 year, 
and to relate preoperative data to the onset of RVF.
For 1-year survival, we performed the log-rank test and 
estimated event-time distributions across AKI stages and 
Fig. 2 Preoperative hemodynamic parameters and their rela-
tion to postoperative right ventricular failure and acute kid-
ney injury early (≤ 30 days) after heart transplantation. An 
illustration of the assessed hemodynamic parameters of the 
heart including RAP; PA systolic, diastolic, and mean pres-
sures (PAmean pressure = [PAsystolic + 2× PAdiastolic]/3); PAPi 
(PAPi = [PAsystolic pressure−PAdiastolic pressure]/RAP); PCWP; RAP-
to-PCWP ratio; TPG (TPG = PAmean pressure−PCWP); DPG 
(DPG = PAdiastolic pressure−PCWP); cardiac output (CO); pulmonary 
vascular resistance (PVR) (PVR = 80 × [PAmean pressure−PCWP]/CO)
; systolic, diastolic, and mean arterial pressure (MAP) 
(MAP = [APsystolic + 2× APdiastolic]/3); systemic vascular resistance 
(SVR) (SVR = 80 × [MAP−RAP]/CO). The asterisk indicates a signifi-
cant predictor of acute kidney injury (AKI). The hash symbol indicates 
a significant predictor of right ventricular failure (RVF). RA right atrium, 
RV right ventricle, PA pulmonary artery, LA left atrium, LV left ventricle, 
Ao aorta
temporal RRT requirements using the Kaplan–Meier 
method. Cox regression analysis was performed to assess 
hazard ratios with 95% confidence intervals for 1-year 
survival.
All analyses were performed with a complete dataset 
using SPSS software (SPSS 20.0; IBMCorp., Armonk, NY, 
USA) and R statistical software using packages ‘pROC’, 
“Hmisc”, and “effects” [22, 24, 25]. All tests were two-
tailed, and p values < 0.05 were considered statistically 
significant.
Results
Incidence and temporal trends of postoperative AKI
From 1984 to 2016, 682 patients underwent HTx at the 
Erasmus MC, of which 595 patients were included in 
this study (Fig. 1). Of 595 patients, 430 (72%) developed 
AKI, including 278 (47%) stage 1, 66 (11%) stage 2, and 
86 (14%) stage 3 AKI. Of those who developed AKI stage 
3, 41 (7%) required RRT which lasted for a median of 
7  days (IQR 5–13) and had a 3.3-times (95%CI 1.6–6.6, 
p = 0.001) higher crude risk of chronic RRT in the first 
year than those who did not require such treatment. Fig-
ure S1 displays the time distribution for the occurrence 
of AKI with the highest peaks for all three stages on the 
seventh day.
We found a tendency towards a higher incidence of 
overall AKI noticeable in recent years. This tendency 
was accompanied by a trend in a lower baseline eGFR 
(median eGFR per 6 5-year intervals 69, 67, 67, 56, 69, 
56  years, p trend < 0.001), an increasing incidence of 
diabetes (0, 3, 10, 9, 13, 13%, p trend < 0.001), and older 
donors (24, 28, 35, 38, 45, 46 years, p trend < 0.001). We 
also found a tendency towards a higher incidence of AKI 
stage 3, but only when defined as a requirement for RRT 
(Fig. S2).
Demographic and perioperative data
Table 1 shows baseline characteristics and perioperative 
data stratified by AKI stages. Patients who had a higher 
AKI stage also had a higher baseline BMI (median 22.6, 
23.2, 22.9, 24.2  kg/m2, p trend < 0.001), a lower baseline 
eGFR (71, 60, 67, 56  ml/min/1.73  m2, p trend < 0.001), 
and more frequent diabetes (4, 7, 8, 13%, p trend = 0.015). 
They also received a heart from older donors (31, 34, 37, 
39  years, p trend < 0.001) with more frequently female 
gender (46, 46, 58, 59%, p trend = 0.019) and postopera-
tively were more frequently diagnosed with RVF (7, 5, 12, 
28%, p trend < 0.001). These patients had a longer hos-
pital stay (20, 24, 24, 37  days, p trend < 0.001) and were 
less likely to have received induction therapy (90, 80, 71, 
67%, p trend < 0.001). A trend was also seen in higher in-
hospital mortality with higher AKI stages (2, 5, 14, 9%, p 
trend = 0.003).
Relationship of preoperative RHH parameters 
with postoperative AKI severity
Figure  2 summarizes the investigated hemodynamic 
parameters. Table  1 shows the values of RHH param-
eters according to the AKI stages. Patients with a higher 
AKI stage also had a higher baseline RAP (median 7, 7, 
8, 11  mmHg, p trend = 0.021) and RAP-to-PCWP ratio 
(0.37, 0.36, 0.40, 0.47, p trend = 0.009) and lower PAPi 
values (2.83, 3.17, 2.54, 2.31, p trend = 0.012).
Table 2 and Fig. S3 display the associations of the sig-
nificant RHH parameters with the risk of postoperative 
AKI severity. In the total cohort, higher RAP and lower 
PAPi values were associated with AKI severity indepen-
dently of the patient’s BMI, baseline eGFR, diabetes, 
donor’s age and sex, ischemia time of the donor’s heart, 
time from right heart catheterization to HTx, postopera-
tive RVF, and the postoperative use of induction therapy 
[adjusted OR (95%CI) per doubling RAP 1.16 (1.02–1.32), 
p = 0.029; PAPi 0.85 (0.75–0.96), p = 0.008]. Moreover, 
we found a significant multiplicative interaction between 
RAP ≥ 6 mmHg and PAPi values (p interaction = 0.034), 
indicating even more pronounced association between 
lower PAPi values and higher probability of AKI severity 
in patients with elevated RAP [adjusted OR per doubling 
of PAPi 0.70 (0.56–0.87), p = 0.002] (Table 2, Fig. S4).
For predicting AKI stage 3, adding each of the hemody-
namic parameters, PAPi and RAP, significantly improved 
the models’ predictive accuracy compared to the best 
clinical model (PAPi IDI = 0.03, p = 0.013 and total con-
tinuous NRI = 0.320, p = 0.007 with 25% reclassification 
for events and 7% reclassification for non-events; RAP 
IDI = 0.02, p = 0.040 and NRI = 0.278, p = 0.018 with 
25% reclassification for events and 3% reclassification for 
non-events). In Fig. 3, AUC analysis also showed signifi-
cant discriminatory improvement [clinical model AUC 
76.1% (95%CI 70.4–81.3), clinical model + PAPi 79.0% 
(73.8–83.8), p delta = 0.044; clinical model + RAP 78.8% 
(73.6–83.5), p delta = 0.049; PAPi alone 60.7% (53.8–
67.1); RAP alone 62.2% (54.6–69.0)]. Based on Youden’s 
index, the best cut-off point for predicting AKI stage 3 
was PAPi < 1.05 and RAP > 11 mmHg. Finally, the associa-
tions of clinical data with postoperative AKI severity are 
shown in Table S1.
Predictors of RVF and its relation to AKI
Of 595 patients, 57 (10%) experienced RVF early after 
HTx. Table S2 shows the predictors of early RVF among 
which the most significant clinical predictors were the 
patients’ impaired baseline eGFR and older donors; 
higher pulmonary artery systolic pressure was the only 
preoperative RHH parameter that predicted RVF. Fur-
thermore, the occurrence of RVF was strongly associated 
with AKI severity (Table S1).
Table 1 Baseline characteristics and perioperative data according to postoperative AKI stages
n (%) No AKI 165 (28) AKI stage 1 278 (48) AKI stage 2 66 (11) AKI stage 3 86 (14) p value
Demographics
 Age, years 51 (45–56) 51 (43–57) 51 (43–57) 48 (41–55) 0.23
 Male sex 127 (77) 208 (75) 49 (74) 67 (78) 0.95
 BMI, kg/m2 22.6 (20.1–24.5) 23.2 (21.0–25.2) 22.9 (20.8–25.8) 24.2 (22.1–26.8) < 0.001*
Renal function
 eGFR, ml/min/1.73m2 71 (58–88) 60 (47–79) 67 (60–79) 56 (43–70) < 0.001*
 eGFR ≥ 90 38 (23) 37 (13) 11 (17) 2 (2) < 0.001*
 eGFR 60–89 79 (48) 103 (37) 40 (60) 33 (38)
  eGFR < 60 48 (29) 138 (50) 15 (23) 51 (60)
  eGFR 45–59 31 (19) 81 (29) 11 (17) 27(32)
  eGFR < 45 17 (10) 57 (21) 4 (6) 24 (28)
Medical history
 Prior cardiac surgery 45 (27) 89 (32) 15 (23) 25 (29) 0.90
 Diabetes mellitus 7 (4) 19 (7) 5 (8) 11 (13) 0.015*
 Hypertension 17 (10) 29 (10) 5 (8) 8 (9) 0.65
Donor characteristics
 Age, years 31 (20–42) 34 (22–45) 37 (24–45) 39 (27–49) < 0.001*
 Male sex 89 (54) 149 (54) 28 (42) 35 (41) 0.019*
Cause of death 0.61
  Trauma 74 (45) 117 (42) 26 (39) 36 (42)
  CVA 83 (50) 149 (54) 38 (58) 4 (51)
  Other 6 (4) 11 (4) 2 (3) 6 (7)
  Unknown 2 (1) 1 (0) 0 (0) 0 (0)
 Time of ischemia donor heart, minutes 165 (139–196) 171 (143–206) 170 (147–195) 176 (150–210) 0.09
Urgency status on waiting list 0.78
 Elective 78 (47) 166 (60) 41 (62) 38 (44)
 Urgent 58 (35) 73 (26) 14 (21) 31 (36)
 Unknown 29 (18) 39 (14) 11 (17) 17 (20)
Preoperative hemodynamic parameters at the time of transplantation listing
 Days before HTx 182 (81–331) 275 (123–545) 273 (117–505) 213 (100–534) 0.15
 Heart rate, beats/min 80 (68–100) 80 (70–92) 73 (61–94) 72 (67–90) 0.06
 Systolic AP, mmHg 99 (90–106) 97 (90–105) 95 (84–105) 97 (87–107) 0.27
 Diastolic AP, mmHg 63 (57–70) 61 (56–69) 62 (54–69) 62 (56–72) 0.91
 Mean AP, mmHg 74 (68–80) 73 (67–81) 73 (64–81) 75 (66–83) 0.61
 Cardiac output, L/min 3.8 (3.1–4.6) 4.0 (3.3–4.7) 3.8 (3.2–4.5) 3.8 (3.0–4.5) 0.98
 PVR, dync/s/cm2 172 (115–230) 149 (96–224) 154 (93–245) 144 (82–226) 0.44
 SVR, dync/s/cm2 1442 (1192–1764) 1286 (1086–1671) 1398 (1216–1605) 1333 (1042–1630) 0.14
 RAP, mmHg 7 (5–12) 7 (4–11) 8 (5–13) 11 (5–17) 0.021*
 PA systolic, mmHg 44 (32–55) 42 (30–52) 44 (34–53) 45 (29–59) 0.93
 PA diastolic, mmHg 23 (15–30) 21 (14–29) 21 (15–30) 23 (15–29) 0.78
 PA mean, mmHg 30 (21–39) 28 (19–36) 27 (21–37) 31 (20–38) 0.84
 PCWP, mmHg 21 (14–29) 20 (13–26) 20 (14–27) 22 (13–29) 0.81
 TPG, mmHg 8.3 (5.0–11.0) 7.7 (4.3–10.7) 7.2 (4.4–10.3) 7.3 (4.3–10.3) 0.25
 DPG, mmHg 1.0 (–2.0–4.0) 1.0 (–2.0–4.0) 0.0 (–2.0–3.0) 0.0 (–2.0–4.0) 0.93
 PAPi 2.83 (1.89–5.81) 3.17 (1.61–5.67) 2.54 (1.82–5.60) 2.31 (1.01–4.57) 0.012*
 RAP-to-PCWP ratio 0.37 (0.24–0.57) 0.36 (0.23–0.52) 0.40 (0.25–0.53) 0.47 (0.29–0.74) 0.009*
Preoperative hemodynamic support
 Inotropes 41 (25) 59 (21) 15 (23) 29 (34) 0.16
 IABP/ECMO 16 (10) 20 (7) 5 (8) 10 (12) 0.68
Relationship of AKI with 1‑year mortality
In total, 51 deaths occurred during the first year after 
HTx with a cumulative mortality of 5, 7, 15, and 14% 
for those without AKI and with AKI stages 1, 2, and 3, 
respectively (log-rank test, p trend = 0.021; Fig. S5a). The 
cumulative mortality was also higher in patients who 
received RRT during the first month than in those who 
had not (22 vs. 8%; log-rank test, p = 0.001, Fig. S5b).
Discussion
To the best of our knowledge, this study is the first to 
assess the predictive properties of different preoperative 
hemodynamic parameters in relation to the occurrence 
of postoperative AKI severity within 30 days after HTx. 
We found that lower PAPi and higher RAP values predict 
AKI severity independently of the recipient BMI, baseline 
eGFR, diabetes, donor age and sex, ischemia time of the 
donor’s heart, time from right heart catheterization to 
HTx, postoperative RVF, and the use of induction ther-
apy. These hemodynamic parameters routinely collected 
at the time of transplantation listing could be used to pre-
dict AKI severity early after HTx.
Although renal injury after HTx has traditionally been 
attributed to the impaired arterial perfusion and CNI 
nephrotoxicity [4], our results illustrate strong evidence 
of the independent relationship between preoperative 
right-sided hemodynamics and AKI severity after HTx. 
One of the potential explanations for this relationship 
may be the long-standing venous congestion that chroni-
cally compromises the kidneys. Subsequently, the kid-
neys may become more vulnerable to the development of 
AKI, especially in cases of postoperative hemodynamic 
instability with hypotensive episodes, or in the settings 
of de novo RVF during the adaptation period of the new 
heart. However, we found that a de novo RVF signifi-
cantly contributed to the development of AKI, but could 
not entirely explain the relationships of preoperative RAP 
and PAPi with the postoperative renal injury. Several 
pathophysiological mechanisms may be responsible for 
this peculiar renal vulnerability, including attenuated vas-
cular reflexes, elevated renal interstitial and intra-tubular 
pressure, activation of the renin-angiotensin-aldosterone 
system, and chronic venous pressure-induced tubule-
glomerular feedback dysfunction [26, 27]. Moreover, we 
found a significant interaction between RAP and PAPi, 
indicating that probabilities of AKI (especially stages 2 
and 3) are markedly increased with lower PAPi values, but 
mostly in patients with elevated RAP (≥ 6 mmHg). These 
findings are supported by Damman et al., who found that 
eGFR starts to significantly decline when RAP increases 
above 6 mmHg [28]. Altogether, it appears that preopera-
tively compromised right-sided venous pressures deserve 
Table 1 continued
n (%) No AKI 165 (28) AKI stage 1 278 (48) AKI stage 2 66 (11) AKI stage 3 86 (14) p value
 LVAD 14 (8) 15 (5) 1 (1) 5 (6)
Postoperative complications
 Right ventricle failure 11 (7) 14 (5) 8 (12) 24(28) < 0.001*
 Re-thoracotomy 12 (7) 18 (6) 9 (14) 12 (14) 0.06
 Primary graft failure 3 (2) 4 (1) 4 (6) 2 (2) 0.14
 Othera 7 (4) 14 (5) 1 (1) 7 (8)
Immunosuppressive therapy
 Induction therapy (yes) 148 (90) 222 (80) 47 (71) 58 (67) < 0.001*
  ATG use 89 (54) 151 (54) 29 (44) 46 (53) 0.58
  Anti-CD3 45 (27) 41 (15) 5 (7) 5 (6) < 0.001*
  Anti-IL2 14 (9) 30 (11) 13 (20) 7 (8) 0.49
 Postoperative delay  CNIb, days 3 (2–5) 3 (1–4) 2 (0–3) 2 (0–5) 0.35
Hospital stay
 Days in ICU 3 (2–4) 3 (2–4) 4 (3–6) 8 (4–14) < 0.001*
 Days in hospital 20 (16–29) 24 (17–33) 24 (17–32) 37 (23–58) < 0.001*
In-hospital mortality 4 (2) 15 (5) 9 (14) 8 (9) 0.003*
Due to uniformity, all continuous data are presented as median and IQR; all categorical data as number and percentage
eGFR estimated glomerular filtration rate, HTx heart transplantation, AP arterial pressure, PVR pulmonary vascular resistance, SVR systemic vascular resistance, 
RAP right atrial pressure, PA pulmonary artery, PCWP pulmonary capillary wedge pressure, TPG trans-pulmonary gradient, DPG diastolic pulmonary gradient, PAPi 
pulmonary artery pulsatility index, IABP intra-aortic balloon pump, LVAD left ventricular assist device, ECMO extracorporeal membrane oxygenator, ICU intensive care 
unit, ATG anti-thymocyte globulins
*p value for a linear trend < 0.05 is statistically significant
a Other includes: perioperative bleeding, cardiac arrest, dosing of inotropes, pacemaker malfunction, acute rejection, and instability of unknown cause
b Postoperative delay after heart transplantation before starting CNI
clinical attention in the context of postoperative AKI and 
may be even more important for kidney functioning after 
HTx than low systemic pressures.
Acute or chronic cardiac dysfunction has negative 
effects on kidney function and vice versa. This complex 
cross-talk was recently described as cardio-renal syn-
drome (CRS) [29]. Chronic HF leading to chronic renal 
congestion in the pre-HTx period is classified as CRS 
type 2. On the other hand, early AKI post-HTx could 
be considered as CRS type 1. Recognition of post-HTx 
CRS may provide possibilities of prevention and treat-
ment strategies in the settings of HTx. Importantly, early 
prediction of postoperative AKI based on preoperative 
RAP and PAPi could help to timely and more proactively 
intervene in the patients who are at high risk, in terms 
of giving more attention to the perioperative volume 
overload, postponing the introduction of nephrotoxic 
CNI, prolonging the support of the right ventricle with 
inotropes, no ventilation, and early introduction of pul-
monary vasodilators (e.g., sildenafil) [11, 27, 30–33]. 
Furthermore, these patients could possibly benefit from 
functional kidney stress tests to assess the renal func-
tional reserve and identify patients who will progress 
to AKI post-HTx [34, 35]. In addition to decreasing val-
ues, PAPi can also go in the opposite direction. Hence, 
the recovery of PAPi values may indicate improvement 
of right-sided pressure, which may be used to optimize 
perioperative hemodynamic support to preserve the kid-
neys from injury. However, prospective studies, prefer-
ably interventional in nature, are needed to elucidate this 
promising concept.
The overall AKI incidence was 72%, which fits at the 
high-end of the reported incidence range of 22–76% in 
HTx recipients [4–7]. This widespread distribution prob-
ably results from the large heterogeneity between stud-
ies and deserves closer attention. Previously, most studies 
reported the older risk injury failure loss end-stage renal 
disease criteria or the acute kidney injury network crite-
ria [6, 36]. However, we used the newer KDIGO criteria 
to define AKI stages [37]. Second, time intervals for the 
occurrence of AKI were different from the present study 
[4–7, 38, 39]. We targeted 1 month as the clinically rel-
evant time interval, whereas previous studies mainly 
focused on the first week [4, 6, 7, 38]. Our results show 
that although all AKI stages peaked on day 7, the risk 
of AKI remains through the first month. This late post-
operative peak of AKI could be attributed to the delay 
in starting of CNI. For this purpose, we use induction 
therapy, especially in patients with impaired kidneys 
and/or hemodynamic instability early after HTx, to post-
pone CNI nephrotoxicity. In our data, the use of induc-
tion therapy was protective for the occurrence of AKI. 
Another important and more worrisome observation is 
that AKI incidence has increased in recent years. This is 
probably explained by an increasing proportion of HTx 
recipients being listed with more comorbidities such as 
chronic renal failure and diabetes, older heart donors, 
and probable changes in clinical management with more 
proactive treatment protocols [2, 40].
Limitations
First, this was a single-center study, and, therefore, the 
clinical management and treatment modalities may differ 
from other transplant centers. However, patient selection 
for transplantation listing and cardiac procedures were 
performed according to generally accepted international 
criteria [11]. Second, its retrospective nature precluded 
Table 2 Associations between preoperative hemody-
namic parameters and postoperative AKI severity early 
after heart transplantation
OR (95% CI) indicates proportional odds ratio with 95% confidence interval; for 
other abbreviations, please see Table 1
*p value < 0.05 is statistically significant
a Total n = 595, no AKI = 165, AKI stage 1 = 278, AKI stage 2 = 66, AKI stage 
3 = 86
b Total n = 340, no AKI = 94, AKI stage 1 = 147, AKI stage 2 = 42, AKI stage 3 = 57
c OR are given per doubling of a preoperative hemodynamic parameter. OR 
are interpreted as the odds of having a more severe renal injury for any level of 
AKI (stage 3, stage 2, stage 1, and no AKI). For example, if RAP increases from 
7 to 14 mmHg (i.e., doubled), the odds of having AKI stage 3 versus combined 
AKI stages ≤ 2 and no AKI are 1.12 times greater. Likewise, the odds of having 
AKI stages ≥ 2 versus combined AKI stage 1 and no AKI are 1.12 times greater. 
Finally, the odds of having AKI of any stage versus no AKI are 1.12 times greater
d OR are given per 10-unit increase in preoperative heart rate (interpretation is 
the same as under c)
e OR are given per 100 dyne/sec/cm2 Increase in preoperative SVR 
(interpretation is the same as under c)
f Preoperative hemodynamic parameters were adjusted for all variables 
with p < 0.10 in univariable analysis and included patient’s BMI, baseline 
eGFR, diabetes, donor’s age and sex, ischemia time of donor’s heart, time 
from catheterization to HTx, postoperative RVF, and the postoperative use of 
induction therapy. Associations between these variables and postoperative AKI 
stages are presented in Table S1
Univariable model Multivariable  modelf
OR (95% CI) p value OR (95% CI) p value
Total  cohorta
 PAPic 0.88 (0.79–0.99) 0.043* 0.85 (0.75–0.96) 0.008*
 RAPc 1.12 (0.99–1.28) 0.07 1.16 (1.02–1.32) 0.029*
 RAP-to-PCWPc 1.19 (1.01–1.39) 0.033* 1.15 (0.98–1.35) 0.10
 Heart  rated 0.90 (0.81–1.00) 0.06 0.98 (0.87–1.11) 0.75
 SVRe 0.96 (0.91–1.00) 0.06 0.96 (0.92–1.01) 0.13
Subgroup RAP ≥ 6 mmHgb
 PAPic 0.74 (0.60–0.92) 0.006* 0.70 (0.56–0.87) 0.002*
 RAPc 1.62 (1.17–2.25) 0.004* 1.78 (1.27–2.50) 0.001*
 RAP-to-PCWPc 1.44 (1.06–1.96) 0.019* 1.31 (0.95–1.08) 0.10
 Heart  rated 0.88 (0.77–1.01) 0.08 0.95 (0.82–1.11) 0.52
 SVRe 0.98 (0.92–1.03) 0.42 0.99 (0.93–1.05) 0.78
the inclusion and evaluation of additional parameters 
such as echocardiography. Furthermore, we were not 
able to analyze the postoperative RHH parameters due to 
unavailability and incompleteness of the historical data. 
Therefore, postoperative RVF could only been retrieved 
as reported or the need for postoperative RVAD. Fur-
ther studies are needed to analyze the incremental value 
of post-HTx RHH parameters. Third, we did not include 
urine output in the definition of AKI because these 
patients were on intensive diuretic therapy, which would 
lead to misinterpretation of the urine output values. 
Altogether, this study is currently the largest HTx cohort 
in which the associations between preoperative hemody-
namics and postoperative AKI were investigated.
Conclusion
Preoperative PAPi and RAP strongly predict the postop-
erative AKI early after HTx and can be used as early AKI 
predictors.
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